论文部分内容阅读
目的:探讨HSP70、bcl蛳2在宫颈癌放疗中的表达及其与预后的关系。方法:采用免疫组织化学法对常规甲醛固定,石蜡包埋的宫颈浸润性鳞癌64例标本,分别检测癌组织中放疗前HSP70、bcl蛳2蛋白的表达,并对其进行定期随访。结果:HSP70在宫颈癌细胞中过表达,其表达与病理分级呈正相关(P < 0.01);与放疗后近期疗效呈正相关(P<0.01);高表达组与低表达组相比1 a、3 a无病生存期显著降低(P<0.01);bcl蛳2蛋白表达与病理分级呈负相关(P <0.05);不表达组放疗后肿瘤消退显著(P <0.01);其1 a、3 a无病生存期显著低于阳性表达组(P <0.05)。结论:HSP70表达水平可以作为宫颈癌细胞增生、分化及远期疗效判定的指标;bcl蛳2蛋白表达可作为远期疗效判定的标志。
OBJECTIVE: To investigate the expression of HSP70 and bcl-2 in radiotherapy of cervical cancer and its relationship with prognosis. Methods: Sixty-four specimens of formalin-fixed and paraffin-embedded cervical invasive squamous cell carcinoma were detected by immunohistochemistry. The expression of HSP70 and bcl-2 protein in cancer tissues before and after radiotherapy were detected and followed up regularly. Results: HSP70 was overexpressed in cervical cancer cells, and the expression of HSP70 was positively correlated with the pathological grade (P <0.01). It was positively correlated with the short-term efficacy after radiotherapy (P <0.01) (P <0.01). The protein expression of bcl-2 was negatively correlated with pathological grade (P <0.05). The tumor regression in non-expression group was significantly (P <0.01) Disease-free survival was significantly lower than the positive expression group (P <0.05). Conclusion: The expression of HSP70 can be used as a marker of cervical cancer cells proliferation, differentiation and long-term efficacy; bcl 蛳 2 protein expression can be used as a marker of long-term efficacy.